@article{APS10230,
author = {Qing Xin and Fei Xu and Devin H. Taylor and Jing-fu Zhao and Jie Wu},
title = {The impact of cannabinoid type 2 receptors (CB2Rs) in neuroprotection against neurological disorders},
journal = {Acta Pharmacologica Sinica},
volume = {41},
number = {12},
year = {2020},
keywords = {},
abstract = {Cannabinoids have long been used for their psychotropic and possible medical properties of symptom relief. In the past few years, a vast literature shows that cannabinoids are neuroprotective under different pathological situations. Most of the effects of cannabinoids are mediated by the well-characterized cannabinoid receptors, the cannabinoid type 1 receptor (CB1R) and cannabinoid type 2 receptor (CB2R). Even though CB1Rs are highly expressed in the central nervous system (CNS), the adverse central side effects and the development of tolerance resulting from CB1R activation may ultimately limit the clinical utility of CB1R agonists. In contrast to the ubiquitous presence of CB1Rs, CB2Rs are less commonly expressed in the healthy CNS but highly upregulated in glial cells under neuropathological conditions. Experimental studies have provided robust evidence that CB2Rs seem to be involved in the modulation of different neurological disorders. In this paper, we summarize the current knowledge regarding the protective effects of CB2R activation against the development of neurological diseases and provide a perspective on the future of this field. A better understanding of the fundamental pharmacology of CB2R activation is essential for the development of clinical applications and the design of novel therapeutic strategies.},
issn = {1745-7254}, url = {http://www.chinaphar.com/article/view/10230}
}